Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 14:14:1123424.
doi: 10.3389/fpsyt.2023.1123424. eCollection 2023.

Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder

Affiliations
Review

Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder

Jonathan Brett et al. Front Psychiatry. .

Abstract

Methamphetamine use disorder is a chronic relapsing condition associated with substantial mental, physical, and social harms and increasing rates of mortality. Contingency management and psychotherapy interventions are the mainstays of treatment but are modestly effective with high relapse rates, while pharmacological treatments have shown little to no efficacy. Psilocybin-assisted psychotherapy is emerging as a promising treatment for a range of difficult-to-treat conditions, including substance use disorders; however, no studies have yet been published looking at psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. Here we review the rationale for psilocybin-assisted psychotherapy as a potential treatment for this indication, and describe practical considerations based on our early experience designing and implementing four separate clinical trials of psilocybin-assisted psychotherapy for methamphetamine use disorder.

Keywords: Addiction Medicine; methamphetamine; methamphetamine use disorder; psilocybin; psilocybin-assisted psychotherapy; stimulant use disorder.

PubMed Disclaimer

Conflict of interest statement

CRN receives funding support from Revive Therapeutics. CSS receives funding support from the Steven & Alexandra Cohen Foundation. CRN and CSS receive psilocybin through Usona Institute’s Investigational Drug Supply Program. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Riddle EL, Fleckenstein AE, Hanson GR. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J. (2006) 8:E413–8. - PMC - PubMed
    1. Davidson C, Gow A, Lee T, Ellinwood E. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev. (2001) 36:1–22. 10.1016/S0165-0173(01)00054-6 - DOI - PubMed
    1. Yu S, Zhu L, Shen Q, Bai X, Di X. Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology. Behav Neurol. (2015) 2015:103969. 10.1155/2015/103969 - DOI - PMC - PubMed
    1. Bonomo Y, Norman A, Biondo S, Bruno R, Daglish M, Dawe S, et al. The australian drug harms ranking study. J Psychopharmacol. (2019) 33:759–68. 10.1177/0269881119841569 - DOI - PubMed
    1. van Amsterdam J, Nutt D, Phillips L, van den Brink W. European rating of drug harms. J Psychopharmacol. (2015) 29:655–60. 10.1177/0269881115581980 - DOI - PubMed

LinkOut - more resources